Clinical Trial Update: Study of Safety and Efficacy of 6 mL Synvisc-One (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment [Phase 4]

View source ↗

Summary

A Phase 4 trial assessed the safety and efficacy of 6 mL Synvisc-One (Hylan G-F 20) in Indian patients with symptomatic knee osteoarthritis after initial and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• Synvisc-One (hylan G-F 20)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Osteoarthritis | Phase 4 | Status: COMPLETED | Results posted: 2015-05-21